Edition:
United States

Dr.Reddy's Laboratories Ltd (RDY.N)

RDY.N on New York Stock Exchange

35.68USD
20 Sep 2017
Change (% chg)

-- (--)
Prev Close
$35.68
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
80,272
52-wk High
$50.06
52-wk Low
$29.85

Select another date:

BRIEF-Dr.Reddy's Labs says FDA completes ‍audit of co's Telangana facilities with no observations​

* FDA completes ‍audit of co's Telangana custom pharmaceutical services facility, technology development centre with no observations​ Source text: http://bit.ly/2hhsmbf Further company coverage:

BRIEF-Dr.Reddy's Laboratories gets EIR from US FDA for Formulation Srikakulam plant

* Says received an establishment inspection report (EIR) from US FDA for formulation Srikakulam plant Source text for Eikon: Further company coverage:

BRIEF-Dr.Reddy's Labs' Aurigene, Curis to start mid-stage study of CA-170

* Says Aurigene Discovery Technologies, Curis plan to initiate phase 2 trial of CA-170 in India‍​

India's Dr Reddy's says German regulator makes 6 observations on unit

Sept 8 Dr. Reddy's Laboratories said on Friday a German regulator has made six major observations about its Duvvada drug making facility in the southern Indian state of Andhra Pradesh, sending shares down as much as 7.1 percent.

BRIEF-Dr.Reddy's Laboratories says Regulatory Authority of Germany concludes audit of facility

* Regulatory Authority of Germany concluded audit of formulations manufacturing facility in Vishakapatnam

BRIEF-Dr. Reddy's Laboratories announces launch of two drugs in U.S. market

* Says announces launch of bupropion hydrochloride extended-release tablets, USP (XL) in U.S. Market

UPDATE 3-London-listed drugmaker Indivior shares crash after U.S. patent blow

* Dr Reddys welcomes ruling (Adds Dr Reddy's comment, further reaction)

BRIEF-Dr.Reddy's Labs says overall impact on financials of settlement disputes with Vivus not likely to be material

* Dr.Reddy's Laboratories clarifies on news item regarding settling patent row with vivus

BRIEF-Dr.Reddy's Labs says ruling in favour of co on generic version of Suboxone doesn't infringe U.S. patents as asserted by Indivior

* U.S. court ruling in favour of co on generic version of suboxone doesn't infringe U.S. patents as asserted by Indivior Source text - http://bit.ly/2eo6WEQ Further company coverage:

UK drug firm Indivior to appeal U.S ruling on Dr Reddy's generic drug

Sept 1 Indivior said on Friday it would appeal against a U.S. court ruling that generic drug maker Dr Reddy's had not infringed its patents, potentially opening the way to a rival to the firm's Suboxone Film opiod addiction treatment.

Select another date: